PHCentral RSS - rss FIRE feed Thu, 18 Sep 2014 11:09:26 GMT Pulmonary Hypertension Targeted Therapy Shows Promise September 19, 2014 N-acetylcysteine: no benefit in idiopathic pulmonary fibrosis September 19, 2014 PANTHER-IPF trial... in an epic demonstration. The more rigorously conducted PANTHER-IPF was stopped early in 2012 due to clear harm resulting from prednisone and azathioprine given to people with idiopathic pulmonary fibrosis.

But one appendage of PANTHER-IPF was allowed to live on: the 81 patients taking N-acetylcysteine (which seemed safe enough), and their placebo-taking controls. Those results were announced at the American Thoracic Society 2014 meeting, and published in the New England Journal in May 2014:

N-acetylcysteine showed no benefit over placebo in the treatment of idiopathic pulmonary fibrosis.
The same national meeting and journal issue announced the exciting success of pirfenidone and nintedanib for slowing lung function decline in IPF, and possibly even preventing IPF exacerbations and extending life for people with idiopathic pulmonary fibrosis.]]>
Protein in 'good cholesterol' may be a key to treating pulmonary hypertension September 18, 2014 Using a rodent model, the researchers showed that a peptide mimicking part of the main protein in high-density lipoprotein (HDL), the so-called "good" cholesterol, may help reduce the production of oxidized lipids in pulmonary hypertension. They also found that reducing the amount of oxidized lipids improved the rodents' heart and lung function]]> Mast Therapeutics’ AIR001 PAH Therapy All-Around Stellar in Phase 2 Clinical Trial September 18, 2014 Researchers Discover Ranolazine May Be a Viable PAH Therapy September 17, 2014 Can Pulmonary Hypertension Be Treated With a Plant? September 16, 2014 ...
Lead author and assistant research scientist at the University of Florida, Gainesville, Vinayak Shenoy, Ph.D., said that among all the available therapies for PH, none target the root of the disease...]]>
Sarcoidosis-Associated Pulmonary Hypertension and Lung Transplantation for Sarcoidosis September 15, 2014
Pulmonary hypertension (PH) is a significant complication of sarcoidosis, occurring in approximately 6 to > 20% of cases, and markedly increases mortality among these patients. The clinician should exercise a high index of suspicion for sarcoidosis-associated PH (SAPH) given the nonspecific symptomatology and the limitations of echocardiography in this patient population. The pathophysiology of PH in sarcoidosis is complex and multifactorial. Importantly, there are inherent differences in the pathogenesis of SAPH compared with idiopathic pulmonary arterial hypertension, making the optimal management of SAPH controversial. In this article, we review the epidemiology, diagnosis, prognosis, and treatment considerations for SAPH. Lung transplantation (LT) is a viable therapeutic option for sarcoid patients with severe pulmonary fibrocystic sarcoidosis or SAPH refractory to...
Pulmonary Arterial Hypertension Study Targets Abnormal Smooth Muscle Cell Growth September 15, 2014 Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH September 14, 2014 Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis September 14, 2014 Combining Gilead’s Ambrisentan and Tadalafil in PAH Clinical Trial Reduced Risk of Clinical Failure September 13, 2014 Mast Therapeutics, Inc. (MSTX) Reports Positive Top Line Phase 2 Data on AIR001,+Inc.+(MSTX)+Reports+Positive+Top+Line+Phase+2+Data+on+AIR001/9812491.html September 13, 2014 Blocking one receptor could halt rheumatoid arthritis September 12, 2014 Use of nebivolol in patients with idiopathic pulmonary hypertension: results of the pilot study September 12, 2014
The researchers concluded: "Therapy with nebivolol in a dose of 5 mg/day for 24 weeks led to a significant functional improvement in the patients with IPH and reductions in RV dimensions and blood ET-1 levels. The therapy did not cause adverse reactions."]]>
Nebivolol and pulmonary hypertension September 12, 2014 Information experiences and needs in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. September 12, 2014 [..]
Conclusions. In the future, healthcare organizations must struggle to achieve a holistic healthcare by making it more person-centred, and they must also promote cooperation between PAH centres and local healthcare providers. It is essential to determine the most appropriate and valuable path of information and communication and, thereby, the most cost-effective management of PAH or CTEPH.]]>
Using plants to produce enzyme may provide treatment for high blood pressure in lungs September 11, 2014 Safe Dosage Established For Experimental Pulmonary Arterial Hypertension Therapy September 11, 2014 Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members. September 10, 2014 Study sheds light on how stem cells can be used to treat lung disease September 10, 2014 United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem’s PLX-PAD Cells for Treatment of Pulmonary Arterial Hypertension September 9, 2014
The Phase I study, being conducted in Australia, is an open-label, dose-escalation study designed to enroll 9 patients diagnosed with PAH. The first cohort of 3 patients has received 0.5 million PLXcells per kilogram body weight. An independent Data Safety Monitoring Board recommended advancement to the second cohort. The second cohort will receive 1 million cells per kilogram, while the third cohort is planned to be administered 2 million cells per kilogram. The primary endpoint of the study is the safety of PLX-PAD cells, which will be evaluated at 12 weeks and one year after dosing. Secondary efficacy endpoints are to be measured at six weeks post-treatment in order to assess changes in the ability to exercise, disease severity and cardio-respiratory function; measures include six-minute walk distance and cardio-pulmonary hemodynamic parameters evaluated via right heart catheterization and echocardiogram...

New Targets for Treating Pulmonary Hypertension Found September 9, 2014 Safety and Sustained Benefits of Adempas® From Bayer Confirmed by Results of Long-Term Studies September 9, 2014 Racial Difference in Sarcoidosis Mortality in the United States. September 8, 2014 Thrombocytopenia is an independent predictor of mortality in pulmonary hypertension September 7, 2014 New Omentin Study Sheds Light On PAH September 7, 2014 Platelets Are Highly Activated in Patients of Chronic Thromboembolic Pulmonary Hypertension September 6, 2014 Bosentan Makes No Impact on PH Associated With Fibrotic IIP September 6, 2014 Potential Therapy Targets for Pulmonary Hypertension ID’d September 5, 2014 Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension September 5, 2014 ]]> Insmed To Present Novel Inhalation PAH Treatment at European Respiratory Society’s International Congress September 5, 2014 United Therapeutics Blocks Generic PAH Drug For Remodulin in Patent Case September 5, 2014 Key Data from Newly-Tested PAH Drug to be Presented at European Conference September 4, 2014 Key protein lowering bad lipids may treat pulmonary hypertension September 3, 2014 First recommendations on all new oral anticoagulants in pulmonary embolism published September 2, 2014 USB Pulse Oximeter Device For COPD Receives FDA Clearance In The U.S. September 1, 2014 What's Going to Be Hot at ERS 2014 August 31, 2014 Pulmonary Hypertension Associated With Chronic Obstructive Lung Disease and Idiopathic Pulmonary Fibrosis August 31, 2014 New Merger Bolsters Development of Drug For Idiopathic Pulmonary Fibrosis, a Disease Associated With PH August 31, 2014 ILH Opens Comprehensive Pulmonary Hypertension Center August 30, 2014 Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model August 30, 2014 Protein in 'good cholesterol' may be a key to treating pulmonary hypertension August 29, 2014 FDA Grants Clearance For Vibralung Acoustical Percussor Respiratory Device August 28, 2014 Pulmonary Hypertension & Viagra: Researchers Discover Novel Mechanisms of Sildenafil for Disease August 27, 2014 How accurate is the TR jet derived Pulmonary artery systolic pressure ? August 26, 2014
At best ,  it has only 40% correlation with cath  derived PAP...]]>
New Report Identifies Key Features in Systemic Sclerosis and PAH August 26, 2014 ]]> Climate Change and Dust Increase Respiratory Disease August 25, 2014 Novel Nitric Oxide Delivery System May Someday Improve PH Treatments August 25, 2014 Gum Disease: a Matter of Life and Death? August 24, 2014 Ranolacine blunts myocardial remodelling in a model of pulmonary hypertension August 23, 2014 A Novel Adipocytokine, Omentin, Inhibits Monocrotaline-Induced Pulmonary Arterial Hypertension In Rats August 22, 2014 [..]
Chronic omentin treatment inhibited MCT-induced increases in PA pressure. Omentin inhibited MCT-induced right ventricular hypertrophy as well as increase of lung to body weight ratio. Histologically, omentin inhibited MCT-induced PA hyperplasia. Further, omentin inhibited the impairment of both endothelium-dependent and -independent relaxations mediated by acetylcholine and sodium nitroprusside, respectively. In conclusion, we for the first time demonstrate that chronic omentin treatment inhibits MCT-induced PAH in rats via inhibiting vascular structural remodeling and abnormal contractile reactivity.

Effects of Bisoprolol and Losartan Treatment in the Hypertrophic and Failing Right Heart. August 21, 2014 The researchers stated: " In our PTB-model of pressure overload induced RV hypertrophy and failure, treatment with bisoprolol and losartan did not demonstrate any beneficial effects in compensated or decompensated RV failure."]]> Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12.;jsessionid=FC357BE55C3A84537439E23637A7F026.f02t03 August 20, 2014 Novel Mechanisms of Sildenafil in Pulmonary Hypertension Involving Cytokines/Chemokines, MAP Kinases and Akt. August 20, 2014